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Abstract
Background—U.S. incidence estimates of pediatric community-acquired pneumonia 
hospitalizations based on prospective data collection are limited. Updated estimates with 
radiographic confirmation and current laboratory diagnostics are needed.
Methods—We conducted active population-based surveillance for community-acquired 
pneumonia requiring hospitalization among children <18 years in three hospitals in Memphis, 
Nashville, and Salt Lake City. We excluded children with recent hospitalization and severe 
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immunosuppression. Blood and respiratory specimens were systematically collected for pathogen 
detection by multiple modalities. Chest radiographs were independently reviewed by study 
radiologists. We calculated population-based incidence rates of community-acquired pneumonia 
hospitalizations, overall and by age and pathogen.
Results—From January 2010-June 2012, we enrolled 2638 (69%) of 3803 eligible children; 
2358 (89%) had radiographic pneumonia. Median age was 2 years (interquartile range 1-6); 497 
(21%) children required intensive care, and three (<1%) died. Among 2222 children with 
radiographic pneumonia and specimens available for both bacterial and viral testing, a viral and/or 
bacterial pathogen was detected in 1802 (81%); ≥1 virus in 1472 (66%), bacteria in 175 (8%), and 
bacterial-viral co-detection in 155 (7%). Annual pneumonia incidence was 15.7/10,000 children 
[95% confidence interval (CI) 14.9-16.5], with highest rates among children <2 years [62.2/10,000 
(CI 57.6-67.1)]. Respiratory syncytial virus (37% vs. 8%), adenovirus (15% vs. 3%), and human 
metapneumovirus (15% vs. 8%) were more commonly detected in children <5 years compared 
with older children; Mycoplasma pneumoniae (19% vs. 3%) was more common in children ≥5 
years.
Conclusions—Pediatric community-acquired pneumonia hospitalization burden was highest 
among the very young, with respiratory viruses most commonly detected.
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Pneumonia is a leading cause of hospitalization among children in the United States1-3 with 
medical costs estimated at almost $1 billion in 2009.4 Despite this large disease burden, 
critical gaps in our knowledge about pediatric pneumonia remain.5
Contemporary estimates of the incidence and etiology of U.S. pediatric community-acquired 
pneumonia hospitalizations would be of value.5 Most recent published pneumonia incidence 
estimates have used administrative data which are limited by inability to apply a strict 
clinical and radiographic definition of community-acquired pneumonia and lack systematic 
diagnostic testing and detailed etiologic data.6 Other existing U.S. pediatric pneumonia 
etiology studies are limited to single sites and short duration.5,7 This is a critical time for an 
etiology study as over the last three decades, pneumococcal conjugate (PCV) and 
Haemophilus influenzae type b (Hib) vaccines have markedly reduced the incidence of 
diseases associated with these pathogens.8-11 Improvements in molecular diagnostics also 
provide new opportunities to improve our knowledge.12,13
The Centers for Disease Control and Prevention (CDC) Etiology of Pneumonia in the 
Community (EPIC) study is a prospective, multicenter, population-based, active surveillance 
study. Systematic enrollment and comprehensive diagnostic methods were used to determine 
incidence and etiology of community-acquired pneumonia requiring hospitalization among 
U.S. children.
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From January 1, 2010 to June 30, 2012, children <18 years old were enrolled in the EPIC 
study at Le Bonheur Children's Hospital (Memphis, TN), Monroe Carell Jr. Children's 
Hospital at Vanderbilt (Nashville, TN), and Primary Children's Hospital (Salt Lake City, 
UT). We sought to enroll all eligible children; thus trained staff screened for enrollment for 
at least 18 hours each day, 7 days each week. Written informed consent was obtained before 
enrollment. The study protocol was approved by the institutional review boards at each 
institution and the CDC. Weekly study teleconferences, required weekly enrollment reports, 
data audits, and annual site visits were conducted to ensure uniform procedures among sites.
Children were included if they 1) were admitted to one of the three study hospitals;2) 
resided in one of the 22 counties in the study catchment areas;3) had evidence of acute 
infection defined as reported fever or chills, documented fever or hypothermia, or 
leukocytosis or leukopenia; 4) had evidence of an acute respiratory illness defined as new 
cough or sputum production, chest pain, dyspnea, tachypnea, abnormal lung examination, or 
respiratory failure; and 5) had chest radiography consistent with pneumonia ≤72 hours of 
admission.
Children were excluded if they were recently hospitalized (<7 days for immunocompetent, 
<90 days for immunosuppressed), enrolled in the EPIC study <28 days earlier, resided in an 
extended care facility, had an alternative respiratory diagnosis, or were newborns who never 
left the hospital. Children with the following were excluded: tracheostomy, cystic fibrosis, 
cancer with neutropenia, solid organ or hematopoietic stem cell transplant ≤90 days earlier, 
active graft-versus-host-disease or bronchiolitis obliterans, or human immunodeficiency 
virus infection with CD4 cell count <200 cells/mm3 (or CD4%<14%).
Data and Specimen Collection
Trained staff obtained blood, acute sera, and naso/oropharyngeal (NP/OP) swabs on all 
enrolled children as soon as possible after presentation. Pleural fluid (PF), endotracheal (ET) 
aspirates, and bronchoalveolar (BAL) specimens obtained for clinical care were also 
collected. Only specimens obtained ≤72 hours of admission were included, except for PF 
(included if collected ≤7 days after admission).
Enrolled children and/or their caregivers were interviewed using a standardized 
questionnaire and medical charts were abstracted after discharge; demographic, 
epidemiologic, and clinical data were systematically collected. Children and their caregivers 
were asked to return 3-10 weeks after enrollment for follow-up interview and convalescent 
serum collection.
Radiographic Confirmation
Enrollment was based on clinicians' initial interpretation of chest radiographs obtained 
within 72 hours of admission. However, final inclusion required independent confirmation 
by the board certified pediatric study radiologist (RAK, JHK, DD) at each study hospital 
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who was blinded to demographic and clinical information. Radiographic evidence of 
pneumonia (hereafter referred to as radiographic pneumonia) was defined as the presence of 
consolidation (a dense or fluffy opacity with or without air bronchograms), other infiltrate 
(linear and patchy alveolar or interstitial densities), or pleural effusion.14 Enrolled children 
who did not meet these criteria were excluded in the final analyses.
Controls
From February 1, 2011 to June 30, 2012, a weekly convenience sample of asymptomatic 
children <18 years old without pneumonia were enrolled and provided NP/OP swabs to 
evaluate the prevalence of respiratory pathogens among asymptomatic children. Eligible 
controls were undergoing outpatient same-day elective surgery at a study hospital, resided in 
the study catchment area in Nashville or Salt Lake City, and were willing to consent and be 
interviewed. Exclusion criteria were the same as for cases; controls were also excluded if 
they had fever or respiratory symptoms within 14 days before or after enrollment (based on 
telephone interview), received live attenuated influenza vaccine ≤7 days before enrollment, 
or were undergoing otolaryngologic surgery.
Laboratory Testing
Gram stain and bacterial culture were performed on blood, PF, ET aspirates, and BAL 
specimens at each site using standard techniques; only high-quality ET aspirates and 
quantified BAL specimens were included (Supplementary Appendix).15,16 Real-time 
polymerase chain reaction (PCR) targeting Streptococcus pneumoniae (lyt-A) and 
Streptococcus pyogenes (spy) genes was performed on whole blood and PF at CDC.17 PF 
was also tested at the University of Utah for H. influenzae and other Gram-negative bacteria, 
Staphylococcus aureus, Streptococcus anginosus/mitis, S. pneumoniae, and S. pyogenes 
using PCR (Supplementary Appendix).18,19 PCR was performed at the study sites on NP/OP 
swabs from children with pneumonia and controls using CDC-developed methods for 
detection of adenovirus (AdV); Chlamydophila pneumoniae; coronaviruses 229E, HKU1, 
NL63, and OC43 (CoV); human metapneumovirus (HMPV); human rhinovirus (HRV); 
influenza A/B viruses; Mycoplasma pneumoniae; parainfluenza viruses 1, 2, 3 (PIV); and 
respiratory syncytial virus (RSV).20-24 Quality assurance and monitoring protocols 
maintained standardization among sites.25,26 Serology for AdV, HMPV, influenza A/B, 
PIV, and RSV was performed at CDC on available paired acute and convalescent sera 
(Supplementary Appendix).27-32
Definition of Pathogen Detection
A bacterial pathogen was defined as detection of H. influenzae and other Gram-negative 
bacteria, S. aureus, S. anginosus/mitis, S. pneumoniae, or S. pyogenes in blood, ET aspirate, 
BAL specimen, or PF by culture, or in whole blood or PF by PCR; or C. pneumoniae or M. 
pneumoniae in a NP/OP swab by PCR. Other bacteria were considered contaminants unless 
they met specific criteria (Supplementary Appendix).
A viral pathogen was defined as detection of AdV, CoV, HMPV, HRV, influenza, PIV, or 
RSV in a NP/OP swab by PCR or by a≥4-fold rise in agent-specific antibody titer between 
acute and convalescent sera for all viruses except HRV and CoV. Determination of 
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influenza serology accounted for influenza vaccination status and timing (Supplementary 
Appendix).32
Co-detection was defined as detection of ≥2 bacterial or viral pathogens in any combination.
Incidence
Annual incidence rates were calculated from July 1, 2010 to June 30, 2011 and July 1, 2011 
to June 30, 2012. To calculate incidence rates, the number of enrolled children with 
radiographic pneumonia was adjusted by age group for the proportion of eligible children 
enrolled at each study site and the proportion of pediatric pneumonia admissions to study 
hospitals in the catchment area (market share) and then divided by the U.S. Census 
population estimates in the catchment area for the corresponding year.33 Market share was 
based on discharge diagnosis codes (Supplementary Appendix).
Pathogen-specific rates for pathogens detected in >1% children were calculated by 
multiplying total pneumonia incidence by the proportion of each pathogen detected among 
children with radiographic pneumonia who had the opportunity for both bacterial and viral 
pathogen detection. To calculate 95% confidence intervals (CI), bootstrap methods with 




Of 3803 eligible children, 2638 (69%) were enrolled; compared with enrolled children, 
eligible but not enrolled children were less likely to be Hispanic and had shorter length of 
stay (Supplementary Table S1).
Of 2638 enrolled children, 2358 (89%) had radiographic pneumonia (Figure 1). Inter-rater 
agreement among the three study radiologists was 84.0% (CI 81.3-86.4) upon review of a 
10% random sample of radiographs. Median age was 2 years old (interquartile range [IQR] 
1-6); 45% were female; 40% were white, 33% were black, and 19% were Hispanic; 51% 
had an underlying condition (asthma/reactive airway disease was most common). Median 
length of stay was 3 days (IQR 2-5); 497 (21%) children required intensive care, and 3 
(<1%) died (Table 1, Supplementary Table S1).
Among children with information, 612 of 2053 (30%) children ≥6 months old received ≥1 
dose of influenza vaccine for the concurrent season and 1101 (87%) of 1272 children aged 
19 months to 12 years old received ≥3 doses of PCV (Supplementary Table S1). Antibiotics 
were prescribed for 18% of children ≤5 days before hospitalization; 88% received 
antibiotics during hospitalization.
Pathogen Detection
Among the 2358 children with radiographic pneumonia, 2254 (96%) had a NP/OP swab, 
2143 (91%) had blood for culture, 2063 (88%) had whole blood for PCR, 1028 (44%) had 
paired sera, 86 (4%) had PF, 23 (1%) had a BAL specimen, and 22 (1%) had an ET aspirate. 
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Among those with collection time available, 82% of 2107 blood cultures and 47% of 2022 
whole blood PCR samples were collected before inpatient antibiotic administration. To 
calculate pathogen-specific proportions, only the 2222 (94%) children with radiographic 
pneumonia for whom blood, PF, ET aspirate, or BAL specimen and a NP/OP swab or paired 
sera were available were used.
A viral and/or bacterial pathogen was detected in 1802 (81%) of 2222 children; ≥1 virus in 
1472 (66%), bacteria in 175 (8%), and bacterial-viral co-detections in 155 (7%). The most 
commonly detected pathogens were RSV (28%), HRV (27%), HMPV (13%), AdV (11%), 
M. pneumoniae (8%), PIV (7%), influenza (7%), CoV (5%), S. pneumoniae (4%), S. aureus 
(1%), and S. pyogenes (<1%) (Figure 2, Supplementary Tables S2, S3). RSV (37% vs. 8%), 
AdV (15% vs. 3%), and HMPV (15% vs. 8%) were more commonly detected in children <5 
years old compared with older children; M. pneumoniae (19% vs. 3%) was more commonly 
detected in children ≥5 years old compared with younger children (Supplementary Table 
S4).
Seasonality
Pneumonia peaked in fall and winter. RSV, influenza, HMPV, and S. pneumoniae increased 
during winter, whereas HRV was detected year-round (Figure 3). M. pneumoniae rose 
steadily from summer through fall 2011, peaking that winter.
Controls
Of 726 controls, 125 (17%) could not be reached for follow-up and 80 (11%) had fever or 
respiratory symptoms after surgery, and were excluded. Among 521 remaining 
asymptomatic controls, 28% were <2 years, 24% were 2-4 years, 24% were 5-9 years, and 
25% were 10-17 years old (Supplementary Table S5). Children with radiographic 
pneumonia (n=832) enrolled during the same period at the same sites were younger; 42% <2 
years, 25% 2-4 years, 19% 5-9 years, and 13% 10-17 years. After adjustment for age, HRV 
was detected in 17% of controls compared with 22% of cases enrolled at the same sites 
during the same period while all other pathogens were detected in ≤3% of controls.
Overall and Pathogen-specific Incidence
Among 2358 children with radiographic pneumonia, 2012 (85%) were enrolled between 
July 1, 2010 and June 30, 2012. The annual incidence of pneumonia hospitalization was 
15.7/10,000 children (CI 14.9-16.5) (Table 2). Incidence was highest among children <2 
years old [62.2/10,000 (CI 57.6-67.1)], lower among those 2-4 years old [23.8/10,000 (CI 
21.4-26.3)], and further decreased with increasing age. Incidence of RSV, HRV, HMPV, 
AdV, influenza, PIV, CoV, and S. pneumoniae was higher among children <5 years old 
compared with older children, but highest among children <2 years old (Supplementary 
Table S6). Incidence of M. pneumoniae was similar across age groups.
Discussion
The multi-center EPIC study is a prospective, population-based U.S. study of pediatric 
community-acquired pneumonia. We demonstrated pneumonia hospitalization burden to be 
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highest among children <5 years old. Multi-pathogen diagnostic testing yielded a pathogen 
in 81% of children with pneumonia; viral and bacterial pathogens were detected in 73% and 
15% of children, respectively.
The annual incidence of community-acquired pneumonia hospitalization estimated from our 
three study hospitals combined was 15.7/10,000 children <18 years old. The estimated 
pneumonia hospitalization rate, using the 2009 national Kids' Inpatient Database, was 
22.5/10,000 children <18 years old2; similar but higher than our rate. These differences 
might be attributed to differences by year, populations studied, and the strict EPIC study 
criteria that included standardized clinical and radiological definitions while excluding 
recently hospitalized or severely immunosuppressed children. Similar to our findings, 
reports using hospital discharge databases have shown decreasing rates of pneumonia with 
increasing age of children.1,3,8
RSV was the most common pathogen detected (28%), with greatest burden among children 
<2 years old with pneumonia. In another study using PCR, RSV was detected among 31% of 
children <14 years old hospitalized with radiographic pneumonia similar to our results.34
HRV was detected in 27% of children with pneumonia. The literature supports that HRV is 
associated with pneumonia, either as a sole pathogen, or in synergy with other 
pathogens.35-37 However, HRV was detected in 17% of controls compared with 22% of 
cases enrolled at the same sites during the same period. Shedding of HRV can extend >2 
weeks after infection,38 making the interpretation of HRV detection among children with 
pneumonia challenging.
HMPV, AdV, PIV, and CoV accounted for one-third of detections, with highest rates among 
children <5 years old. In similar pediatric pneumonia studies, these pathogens accounted for 
25-40% of detections.12,34 In our study, although PCR was responsible for the majority of 
viral detections, serology was a useful adjunct.27,28 Our study occurred after the 2009 H1N1 
pandemic when the influenza seasons were mild;39 making the influenza burden less than 
during seasons with more widespread circulation.
Bacterial pathogens were detected in 15% of children with pneumonia. While the incidence 
of M. pneumoniae was fairly similar across age groups, M. pneumoniae accounted for a 
steadily increasing proportion of pneumonia with increasing age.40 An earlier U.S. pediatric 
pneumonia etiology study using PCR targeting pneumolysin, a test with limited 
specificity,7,41 and conducted before universal Hib and PCV use reported a higher 
proportion of bacterial detection than we demonstrated.7 While our data partly reflect the 
substantial reduction of pneumococcal and Hib disease due to conjugate vaccines, bacterial 
culture-based diagnostics have limited sensitivity and bacteremia is detected in a minority of 
pneumococcal pneumonias.8-11,41,42 In the absence of a gold standard for bacterial pathogen 
detection in pneumonia, our findings based on current state-of-the-art diagnostics suggest 
that the incidence of bacterial pneumonia is lower than previously reported.
In our study, the proportion of pathogen co-detection was 26%. Another U.S. etiology study 
of 154 children hospitalized with community-acquired pneumonia reported an identical 
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prevalence.7 Given the large proportion and diversity of co-detections, further study is 
needed.
This study has several limitations. Not every eligible child was enrolled; although incidence 
calculations accounted for non-enrollment. Among enrolled children, not all specimen types 
were available, potentially leading to under- or over-estimation of pathogen-specific rates; 
however, 94% of children with radiographic pneumonia had specimens available for both 
bacterial and viral detection and no demographic or clinical differences were noted between 
those with and without specimens available. Despite a comprehensive diagnostic approach, 
sensitivity of current tests for bacterial pneumonia (particularly in the setting of antibiotic 
use), is not optimal.43,44 Due to ethical and feasibility considerations, invasive procedures to 
obtain direct lung samples were not commonly performed. PCR detection of pathogens in 
NP/OP swabs could represent infection limited to the upper tract or convalescent shedding 
and thus detection may not denote causation. Our controls were a convenience sample and 
may not have represented the underlying population; their enrollment was not done for the 
entire study duration, was restricted to two sites, and focused on the prevalence of pathogens 
in asymptomatic children thus limiting extrapolations of causality. However, except for 
HRV, pathogens were uncommonly detected in controls, suggesting that the other viruses 
and atypical bacteria contribute to pneumonia. We believe control data helped interpret 
pathogen detections among cases and is an important strength. There is substantial overlap 
in clinical and radiologic features between bronchiolitis, reactive airway disease, and 
pneumonia, particularly in young children. Even strict radiographic definitions may not 
accurately distinguish these entities resulting in potential misclassification.45 Finally, 
although our multi-center study allowed investigation of diverse populations with 
standardized procedures, our findings may not be representative of the entire U.S. pediatric 
population or generalizable to other settings.
In conclusion, the burden of community-acquired pneumonia requiring hospitalization was 
highest among younger children, with respiratory viruses frequently detected. Effective anti-
viral vaccines or treatments, particularly for RSV, could have an impact on pediatric 
pneumonia. The low prevalence of bacterial detections likely reflects both the effectiveness 
of bacterial conjugate vaccines and relatively insensitive diagnostics. The pediatric 
community-acquired pneumonia burden was associated with multiple different and co-
detected pathogens, underscoring a need for the enhancement of sensitive, inexpensive, and 
rapid diagnostics to accurately identify pneumonia pathogens.
Supplementary Material
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Figure 1. Study Enrollment and Final Pneumonia Cases
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Figure 2. A/B: Pathogen Detection among U.S. Children with Community-acquired Pneumonia 
Requiring Hospitalization, 2010-2012
Panel A shows the proportion of pathogen types detected from January 1, 2010 through June 
30, 2012 among 2222 hospitalized children with radiographic pneumonia who had 1) blood 
(bacterial culture or real-time polymerase chain reaction [PCR]) or pleural fluid (bacterial 
culture or PCR), endotracheal aspirate (bacterial culture), or bronchoalveolar lavage 
(bacterial culture); 2) and naso/oropharyngeal swab (viral and atypical bacterial PCR) or 
viral serology results available. Panel B shows number and percent of children with specific 
pathogen detections for all ages in the bar graph. There were 1802 patients who had a viral 
and/or bacterial pathogen detected among 2222 patients who had available tests for both 
bacterial and viral detection; there were two patients in whom Histoplasma was detected. 
Because patients could have more than one pathogen detected, there were a total of 2533 
total detections. Darker and lighter shading in the bar graph indicates single and co-pathogen 
detection, respectively. Proportions of detections (single and co-detection) by age group are 
depicted on the pie graphs.
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A/B: Pathogen Detection by Month and Year among U.S. Children with Community-
acquired Pneumonia Requiring Hospitalization, January 1, 2010 through June 30, 2012. 
Panel A includes respiratory syncytial virus (RSV), human rhinovirus (HRV), human 
metapneumovirus (HMPV), adenovirus (AdV), and influenza A/B (Flu). Panel B includes 
M. pneumoniae (M. pn), parainfluenza viruses 1-3 (PIV), coronaviruses (CoV), and S. 
pneumoniae (S. pn.).
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Table 1
Characteristics of Children with Community-acquired Pneumonia Requiring 
Hospitalization
Characteristic Children with radio graphic confirmation of pneumonia (n=2358)
Age groups – no. (%)
 <2 years 1055 (45)
 2-4 years 595 (25)
 5-9 years 422 (18)
 10-17 years 286 (12)
Symptoms – no. (%)
 Cough 2230 (95)
 Fever/feverish 2155 (91)
 Anorexia 1766 (75)
 Dyspnea 1657 (70)
Any underlying condition* – no. (%) 1197 (51)
 Asthma/reactive airway disease 779 (33)
 Pre-term birth among children <2 yrs. 218/1055 (21)
Radiographic findings† – no. (%)
 Consolidation 1376 (58)
 Alveolar or interstitial infiltrate 1195 (51)
 Pleural effusion 314 (13)
Hospitalization characteristics – no. (%)
 Length of stay – median days, IQR 3 (2-5)
 Intensive care unit admission 497 (21)
 Mechanical ventilation 166 (7)
 Death (in-hospital) 3 (<1)
*
Any underlying medical conditions included asthma/reactive airway disease, chromosomal disorders including Down syndrome, chronic kidney 
disease, chronic liver disease, congenital heart disease, diabetes mellitus, immunosuppression (either due to chronic condition or medication, 
malignancy [but not skin cancer], human immunodeficiency virus infection with CD4 count >200 cells/mm3), neurological disorders (including 
seizure disorder, cerebral palsy, scoliosis), pre-term birth (defined as gestational age <37 weeks at birth for those children who were <2 years old at 
time of hospitalization), and splenectomy. A more complete list of the prevalence of specific conditions is in Supplementary Table S1.
†
Findings are not mutually exclusive and therefore do not add to 100%; only 6 children had pleural effusion alone.
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Table 2
Estimated Annual Incidence Rates* of Community-acquired Pneumonia Hospitalization 
by Year, Site, Age Group, and Pathogen Detected
Variable Annual no. pneumonia hospitalizations/10,000 children 95% confidence interval
Overall incidence rate† 15.7 14.9–16.5
 2010-2011 (year 1) 16.8 15.6-18.0
 2011-2012 (year 2) 14.6 13.5-15.7
Study Site
 Memphis 19.6 18.0–21.3
 Nashville 12.3 11.2–13.4
 Salt Lake City 15.2 13.8–16.5
Age group
 <2 years 62.2 57.6–67.1
 2-4 years 23.8 21.4–26.3
 5-9 years 10.1 8.9–11.3
 10-17 years 4.2 3.6–4.8
Pathogen-specific incidence‡
 Respiratory Syncytial Virus 4.6 4.3–5.1
 Human Rhinovirus 4.1 3.7–4.4
 Human Metapneumovirus 1.9 1.6–2.1
 Adenovirus 1.6 1.4–1.8
 Mycoplasma pneumoniae 1.4 1.2–1.6
 Influenza A/B virus 1.1 0.9–1.3
 Parainfluenza viruses 1-3 0.9 0.8–1.1
 Coronaviruses 0.8 0.7–1.0
 Streptococcus pneumoniae 0.5 0.4–0.6
*
Based on 2,212,327 person-years of observation
†
Annual incidence rates were calculated from July 1, 2010 to June 30, 2011 (year 1) and July 1, 2011 to June 30, 2012 (year 2) and represent the 
2012 children with radiographic pneumonia enrolled during that time
‡
Pathogen-specific incidence is calculated for the 1899 children with radiographic pneumonia during the incidence period with at least one 
specimen available for both bacterial and viral testing. Age-specific pathogen-specific incidence is in Supplementary Table S6.
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